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ABSTRACT 
Background: Surveillance in patients with previous polypectomy was underused in the 
Medicare population in 1994. This study investigates whether expansion of Medicare 
reimbursement for colonoscopy screening in high-risk individuals has reduced the 
inappropriate use of surveillance.  
Methods: We used Kaplan-Meier analysis to estimate time to surveillance and polyp 
recurrence rates for Medicare beneficiaries with a colonoscopy with polypectomy between 
1998 and 2003 who were followed through 2008 for receipt of surveillance colonoscopy. 
Generalized Estimating Equations were used to estimate risk factors for: 1) failing to 
undergo surveillance and 2) polyp recurrence among these individuals. Analyses were 
stratified into three 2-year cohorts based on baseline colonoscopy date. 
Results: Medicare beneficiaries undergoing a colonoscopy with polypectomy in the 1998-
1999 (n=4,136), 2000-2001 (n=3,538) and 2002-2003 (n=4,655) cohorts had respective 
probabilities of 30%, 26% and 20% (p<0.001) of subsequent surveillance events within 3 
years. At the same time, 58%, 52% and 45% (p<0.001) of beneficiaries received a 
surveillance event within 5 years. Polyp recurrence rates after 5 years were 36%, 30% and 
26% (p<0.001) respectively. Older age (≥ 70 years), female gender, later cohort (2000-
2001 & 2002-2003), and severe comorbidity were the most important risk factors for failure 
to undergo a surveillance event. Male gender and early cohort (1998-1999) were the most 
important risk factors for polyp recurrence.   
Conclusions: Expansion of Medicare reimbursement for colonoscopy screening in high-
risk individuals has not reduced underutilization of surveillance in the Medicare population. 
It is important to take action now to improve this situation, because polyp recurrence is 
substantial in this population. 
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INTRODUCTION 
Individuals in whom adenomas have been detected are considered to be at 
increased risk of developing colorectal cancer (CRC), even after the adenomas have been 
removed (1). These high-risk individuals are therefore recommended to undergo regular 
surveillance with colonoscopy (every five years if 1-2 adenomas smaller than 1 cm, every 
3 years otherwise) (2). Colonoscopic polypectomy and subsequent surveillance have been 
estimated to reduce CRC incidence by 76-90% (1) and mortality by 53% (3) in adenoma 
patients. In patients aged 50 years and older, surveillance after adenoma removal is the 
single most common indication for colonoscopy (4). Two studies evaluating the utilization 
of surveillance colonoscopy in adenoma patients were recently published (5, 6). Both 
studies concluded that surveillance colonoscopy was overused in low-risk subjects, while 
concurrently being underused in higher-risk subjects.  
The subjects in the aforementioned studies showing underutilization were 
volunteers in the polyp prevention trial (5) and the Prostate, Lung, Colorectal and Ovarian 
Cancer screening trial (6). Volunteers in clinical trials are known to be more health 
conscious and may consequently be more desirous and demanding of frequent 
colonoscopy examinations. Their colonoscopy utilization patterns may therefore not be 
representative of the general US population and may underestimate the true problem of 
underuse in the population, while at the same time overestimating overuse. SEER-
Medicare is generally representative of the elderly (65+ year-old) population and will as 
such provide better insight into the under- and overuse of surveillance in the general 
population, at least those aged 65 years and older, representing 67% of CRC (7). 
A previous study of surveillance patterns in the Medicare population showed that 
25% of patients with previous polypectomy did not undergo a surveillance event within 5 
years (8). At the same time a high likelihood of polyp recurrence of more than 50% within 5 
years was observed in those with surveillance, underscoring the need for compliance with 
surveillance recommendations. On the other hand, more than 50% of patients with 
previous polypectomy received surveillance within the shortest recommended surveillance 
4 
 
interval of 3 years. This study was conducted in a cohort of Medicare beneficiaries in 1994, 
before coverage of colonoscopy screening for high-risk individuals including adenoma 
patients was introduced in 1998. In the current study, we investigated whether expansion 
of Medicare reimbursement for colonoscopy screening in high-risk individuals has affected 
the under- and overutilization of surveillance in this population.  
 
METHODS 
Data Source 
The study population consisted of the 5% sample cohort of Medicare beneficiaries 
without cancer who reside in SEER areas obtained along with the SEER-Medicare 
database, a collaborative effort of the National Cancer Institute, the SEER registries, and 
the Centers for Medicare & Medicaid Services (9, 10). All non-cancer SEER-Medicare 
enrollees (aged 66 and older) with full coverage in Part A, Part B and no Health 
Maintenance Organization (HMO) coverage for 24 consecutive months after a claim for a 
colonoscopy with index polypectomy between 1998 and 2003 were included in the study 
and followed until December 31, 2008. To ensure that colonoscopies were being 
performed for surveillance purposes, we excluded individuals with a cancer diagnosis 
before or at baseline colonoscopy or two claims of any one of the following diagnoses (for 
which colonoscopy may constitute part of work up) indicated 12 months before 
polypectomy: colitis and enteritis (International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9) codes 009.0, 009.1, 555.1-555.2, 555.9, 556, 558), iron 
deficiency anemia (280.9), chronic vascular insufficiency of intestine (557.1), unspecified 
intestinal obstruction (560.9), diverticula (562.1), stenosis (569.2), hemorrhage (569.3, 
578.9), ulceration (569.41, 569.82), colostomy and enterostomy complications (569.6), 
perforation (569.83), filling defects (793.4), rupture (537.83-537.89), or other disorders of 
the intestine (546.81-546.89, 569.85-569.86). 
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Analysis 
To assess under- and over-utilization of surveillance in individuals with 
polypectomy, we selected beneficiaries with at least a baseline polypectomy between 
1998 and 2003. Polypectomy claims were identified by searching outpatient and 
physician/supplier claims files, using Health Care Common Procedure Coding System 
(HCPCS) codes 45383, 45384, 45385; and ICD-9 codes 45.42, 45.43, 48.36. We used 
Kaplan-Meier analysis to estimate the probability of undergoing a subsequent surveillance 
event over time. A surveillance event was defined as follow-up by colonoscopy (HCPCS 
codes G0105, G0121, 45378, 45380, 45383, 45384, 45385; and ICD-9 codes 45.23, 
45.25, 45.42, 45.43, 48.36), sigmoidoscopy (HCPCS codes G0104, 45330, 45331, 45333, 
45338, 45339, 45300-45320; and ICD-9 codes 45.24, 48.23, 48.24) or barium enema 
(HCPCS codes G0106, G0120, 74270, 74280). To investigate changes over time, for 
example because of expansion of reimbursement in 2001, the analysis was stratified by 
time of baseline colonoscopy: 1998-1999, 2000-2001 and 2002-2003. Individuals were 
included in a cohort if they had a polypectomy within the selected time period. The 
baseline colonoscopy was defined as the first colonoscopy with polypectomy for an 
individual within the selected time period. As such, one individual could contribute to all 
three cohorts, if this person had a colonoscopy with polypectomy in each of the specified 
time periods. However, an individual could only contribute once within a cohort. Time was 
measured from the baseline colonoscopy to the time of subsequent surveillance event or 
censoring because of:  
1. End of enrollment of fee-for-service Part A or B, or enrollment in HMO 
2. Two diagnoses of any of the above-mentioned comorbidities following index 
 polypectomy 
3. Death or 
4. End of follow-up period (December 31, 2008) 
To account for subjects brought back early for clinical concerns, repeat colonoscopy, 
sigmoidoscopy or barium enema examinations performed within 6 months of the baseline 
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colonoscopy were considered part of the baseline procedure and potential polypectomies 
at those examinations were included with the baseline results. Appendix 1 provides an 
overview of how patients included in the study were followed over time and included in the 
analyses.  
Kaplan-Meier survival curves were used to estimate utilization of surveillance in the 
Medicare population with previous colonoscopy with polypectomy over time. Survival 
curves were also used to estimate polyp recurrence rates for only those subjects who had 
a surveillance event combined with a polypectomy. We used 5-year survival estimates as 
the basis for comparison between cohorts. In addition, we used Generalized Estimating 
Equations (GEE) to estimate risk factors for failure to undergo surveillance within 5 years 
in this population. We also used GEE to estimate risk factors for subsequent polypectomy 
during surveillance in all patients that had surveillance, accounting for patient-level 
clustering as patients were allowed to contribute to more than one cohort (11). We could 
not use logistic regression because observations were not completely independent due to 
repeated measures for the same patient. Patient characteristics considered in the model 
included age, race/ethnicity, gender, Charlson comorbidity score (including comorbidities 
developed after baseline colonoscopy) (12), and urban versus rural status.  
All analyses were performed using SAS software (version 9.2; SAS Institute Inc, 
Cary, NC). 
Sensitivity Analysis 
 We performed the following sensitivity analyses: 
1. Inclusion of patients with polyps detected and removed at (procto-) sigmoidoscopy 
(HCPCS: 45333, 45338, 45339, 45308, 45309, 45315, 45320)  
2. Single inclusion of individuals in the cohort of their first colonoscopy with 
polypectomy between 1998 and 2003. (Individuals contributed to a single cohort) 
3. Limiting the definition of a surveillance event to a colonoscopy and 
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4. Including patients diagnosed with CRC from the SEER-Medicare data between 
1998-2003 who had at least 1 polypectomy more than 6 months before their 
diagnosis date. 
 
IRB approval 
The Institutional Review Board of Morehouse School of Medicine determined the 
study appropriate for exemption under federal regulations.  
 
RESULTS 
There were 3,538 Medicare beneficiaries with a polypectomy in 1998-1999, 4,136 
in 2000-2001 and 4,655 in 2002-2003 fulfilling our inclusion criteria. The characteristics of 
the population for each of these cohorts are presented in Table 1. Approximately 55% of 
the patients in each cohort were women and the vast majority lived in urban areas. The 
age and race distribution differed between cohorts, with the 1998-1999 cohort having 
relatively more white people and people between ages 66-69 years than the 2000-2001 
and 2002-2003 cohorts. Approximately 65% of the population had or developed a 
Charlson comorbidity score of 1 or more. Of the people that received a surveillance event, 
around 98% received a colonoscopy.  
Patients without a surveillance event were followed for a mean period of 5.1-6.4 
years, depending on cohort. Among the 6,985 patients with surveillance, 47% of 
surveillance events occurred within 3 years, and 83% within 5 years. Mean follow-up until 
surveillance was 3.2-3.4 years. A Kaplan-Meier probability curve of surveillance utilization 
is presented in Figure 1. The cumulative probability of a surveillance event within three 
years decreased from 31.5% in the 1998-1999 cohort to 20.0% in the 2002-2003 cohort 
(p<0.001). At the same time, however, the cumulative probability of a subsequent 
surveillance event within 5 years also significantly decreased from 58% to 45% 
respectively (p<0.001). Consequently, the probability of failure to undergo a surveillance 
event within 5 years increased from 42% to 55% in this period.  
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GEE regression identified older age, female gender, later cohort and high 
comorbidity as factors associated with failure to undergo subsequent surveillance (Table 
2). The highest odds ratios were found for older age (increasing to 3.7 [95% CI: 3.0-4.4] for 
people aged 85 years and older compared to people aged 66-69 years) and severe 
comorbidity (increasing to 2.2 [95% CI: 2.0-2.4] for a comorbidity score of 2+ compared to 
those without comorbidity) (p<0.001). Rural status and race were not significantly 
associated with failure to undergo subsequent colonoscopy.  
The cumulative probability of polyp recurrence (Figure 2) within 5 years also 
significantly decreased from 36% in the 1998-1999 cohort to 26% in the 2002-2003 cohort 
(p<0.001). However, these estimates are still high, showing that 58% of all surveillance 
events within 5 years result in another polypectomy. Among people with a surveillance 
event within 5 years, male gender and early cohort were both associated with higher polyp 
recurrence rates (Table 3), with male gender being the most important one. The odds ratio 
for polyp recurrence in men compared to women was 1.4 (95% CI: 1.2-1.5). Age, race, 
rural status and comorbidity status were not significantly associated with polyp recurrence.  
 
Sensitivity Analysis 
 Our results were robust for the sensitivity analyses we performed. The 5-year 
probabilities of surveillance and polyp recurrence stayed within 6%-points of the original 
estimates (Table 4). Results were most influenced by limiting the inclusion of individuals to 
their first polypectomy (probability of surveillance event within 5 years decreased from 
45% to 40% for the 2002-2003 cohort), and inclusion of cancer cases (probability of 
surveillance event increased from 58% to 64% for the 1998-1999 cohort). In all sensitivity 
analyses, the risk factors for failure to undergo surveillance and polyp recurrence from the 
GEE models did not change (data not shown).  
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DISCUSSION 
 This study shows that overuse of surveillance within 3 years after a polypectomy 
decreased from 31.5% for Medicare beneficiaries with a baseline polypectomy in 1998-
1999 to 20% in 2002-2003. However, at the same time underuse of surveillance increased 
from 42% of Medicare beneficiaries with polypectomy in 1998-1999 not receiving 
surveillance within 5 years to 55% 2002-2003. Especially, women, the elderly and people 
with serious comorbidities were less likely to receive timely surveillance. This study also 
shows that timely surveillance is important, because approximately 60% of Medicare 
beneficiaries with polypectomy and subsequent surveillance are found to have another 
polyp. Polyp recurrence is especially high in the male Medicare population. 
 Our results were robust to alternative inclusion criteria explored in the sensitivity 
analyses. Limiting inclusion of individuals to their first colonoscopy with polypectomy 
between 1998 and 2003 decreased the probability of surveillance the most (by 5%-points 
in the 2002-2003 cohort). This was expected, because in this sensitivity analysis, patients 
that undergo regular surveillance were excluded from later cohorts, leaving patients with 
irregular surveillance overrepresented. Including cancer cases and assuming that all 
cancer diagnoses between 6 months and 5 years after polypectomy were surveillance 
detected cancers, increased probability of surveillance the most, by 6%-points. It is 
unlikely that all cancer cases were surveillance detected, but even under this extreme 
assumption, the probability of surveillance did not exceed 64% and was still decreasing 
over time to 45% in the 2002-2003 cohort.  
 With the introduction of Medicare coverage of colonoscopy screening for high-risk 
individuals in 1998, we anticipated an increase in surveillance rates for this population but 
found decreased rates. Possible explanations for this unexpected finding include the 
growing recognition that surveillance in many settings can and should be done less 
frequently (e.g. every 10 years in case of 1 tubular adenoma) (13). Furthermore, 
reimbursement of colonoscopy screening may have triggered a different selection of 
people to undergo colonoscopy. In the early years, our study probably consisted mostly of 
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high-risk patients with a family history of CRC, while in later years more people without 
family history (and lower likelihood of advanced adenomas) were likely included in our 
study as Medicare expanded colonoscopy coverage from only high-risk individuals in 1998 
to all individuals in 2001. Patients with family history are more likely to have advanced 
adenomas and these two factors have been shown to synergistically influence 
colonoscopy utilization (6). The later cohort may not be deemed as high-risk by treating 
physicians, compared with the original set of people with symptoms and family history, and 
may therefore not receive an intensive surveillance recommendation. Another explanation 
for the decrease in surveillance rates might be the improvement in the quality of 
colonoscopy, such as use of high-definition endoscopes and use of split-dose preparation. 
As a consequence of these techniques, treating physicians may be more confident of 
having completely cleared the colon, recommending longer surveillance intervals. In 
addition, higher quality colonoscopy may have resulted in increased detection rates of 
diminutive polyps. Diminutive polyps are more often non-neoplastic (14) and people with 
non-neoplastic polyps are not recommended to undergo regular surveillance (2). Both 
explanations are supported by the increasing number of people receiving baseline 
colonoscopy with polypectomy (33% increase from 1998-1999 to 2002-2003) likely 
influencing the composition of the population. However, both also remain speculative and 
need further investigation.  
 Our estimates for the probability of inappropriate surveillance within 3 years (20-
31%) are considerably lower than those reported in surveys among primary care 
physicians and endoscopists: in these surveys more than 50% of physicians 
recommended surveillance within 3 years for people with a hyperplastic polyp or small 
tubular adenomas only (15, 16). More recent estimates based on medical chart review 
indicate that approximately 24% of patients with hyperplastic polyps only were 
recommended to undergo surveillance within 4-6 years and 35% of patients with only 
small adenomas were recommended to return within 1-3 years (17), which is more in line 
with our estimates.  
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Our estimates for the probability of a surveillance event within 5 years for Medicare 
beneficiaries in the 2002-2003 cohort (45%) are considerably lower than those found by 
Amonkar et al (74%) (8) in a study cohort with index colonoscopies in 1994. Even though 
our findings differ from those of Amonkar et al., our results mirror those of Cooper at al. 
(18), whose study cohort reflects the same timeframe. Cooper et al. found a decreasing 
trend in surveillance utilization for more recent index colonoscopies. Thus, practice pattern 
changes in more recent years are a very plausible explanation.  Possible explanations for 
the difference between our results and those of Amonkar et al. are the inclusion of people 
with prevalent polyps (i.e. a diagnosis of colorectal polyp before the baseline colonoscopy) 
in Amonkar’s study and the exclusion of individuals with gastrointestinal comorbidities for 
which colonoscopy may constitute part of standard work up in our study. Our findings are 
also consistent with findings from studies of surveillance of adenoma patients in other 
health care settings. Laiyemo et al. found a probability of a surveillance colonoscopy in 
adenoma patients of 59.7% after a mean follow-up time of 5.9 years (5). In the study by 
Schoen, surveillance probabilities after 5 years varied from 46.7% to 58.5% depending on 
the number and type of adenomas found (6).  
 Risk factors for failure to receive subsequent surveillance are also the ones 
associated with the lowest polyp recurrence rates: later cohort and women. The lower 
polyp recurrence in later cohorts can be explained by higher failure rates to undergo a 
surveillance event. Interestingly age was not found to be a predictor for polyp recurrence, 
while older age has been consistently found to be an independent predictor for (advanced) 
adenoma recurrence (19, 20). When age is investigated as a potential risk factor, age is 
often dichotomized into younger than 60 and 60 years and older (20). The fact that all 
individuals in our study were into the latter category, might explain why we did not see an 
age effect. Amonkar et al found polyp recurrence to decrease with the age of the patient in 
Medicare (8). They suggested that frailty of the patient might play a role, and that 
physicians suggest less aggressive treatments for patients in the oldest age groups, 
because of increased risk of complications (21). It has been suggested that removal of 
12 
 
diminutive polyps could be foregone, especially in older individuals as death from other 
causes is likely to occur before these polyps become invasive tumors (22).  
Several limitations are noteworthy. First, this study is based on administrative data 
that were not collected for research purposes. As a consequence, the data may contain 
errors due to billing and coding. However, a study investigating the accuracy of Medicare 
claims for measuring colorectal endoscopy use concluded that Medicare claims can 
provide accurate information on whether a patient has undergone colorectal endoscopy 
and may be more complete than physician medical records (9). A second study 
investigating the accuracy of Medicare claims for identifying findings and procedures 
performed during colonoscopy concluded that Medicare claims have high sensitivity and 
specificity for polyp detection, biopsy, and polypectomy at colonoscopy (23).  
Second, it cannot be distinguished from Medicare data whether subsequent 
colorectal examinations were performed for surveillance purposes or for clinical reasons. 
This was also confirmed by Schenck et al., suggesting that researchers who use Medicare 
claims to assess rates of colorectal testing should include both screening and diagnostic 
endoscopy procedures in their analyses (9). In this analysis, we included both types of 
procedures as recommended, but we tried to exclude colorectal examinations for clinical 
reasons by excluding people with comorbidities prior to baseline colonoscopy that may 
require repeat colonoscopies for reasons other than adenoma findings. As a result of that 
exclusion, the population in this study will be somewhat healthier than the average 
Medicare population. Third, our study only includes patients enrolled in fee-for-service and 
not HMO. HMO patients are shown to have higher stage at diagnosis for CRC, which may 
indicate lower utilization since 2000 (24).   
Fourth and most importantly, Medicare claims data lack information on clinical 
polyp characteristics such as number of polyps and size and histology of the polyps 
removed. As a result not all beneficiaries in our cohorts may have actually had an 
adenoma removed, but could also have had a non-adenomatous polyp removed. 
Surveillance exams are not recommended for people with these types of polyps (2), and 
13 
 
we may have therefore underestimated the probability of timely surveillance in our 
analysis. In several studies in an average-risk (screening) population, approximately half of 
people with polyps have been found to have non-adenomatous polyps only (14, 25, 26). In 
our study approximately 50% of patients with polypectomy did not receive surveillance. In 
theory, these could all be individuals with non-adenomatous polyps only, and then the 
probability of timely surveillance would actually be near-perfect. Given the careful 
sensitivity analyses performed and the consistencies between our estimated surveillance 
probabilities and that of other community-based studies (5, 6), near-perfect surveillance is 
unlikely.   
In conclusion, our study shows that expansion of Medicare reimbursement for 
colonoscopy screening in high-risk individuals in 1998 has not reduced the underutilization 
of surveillance in the Medicare population. Surveillance rates after polypectomy have 
further declined between 1998 and 2003. Measures should be taken to increase 
surveillance uptake, because polyp recurrence is substantial in this population.   
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Figure 1 Kaplan-Meier estimates of probability of first surveillance event, stratified by 
cohort based on date of baseline colonoscopy with polypectomy.   
 
Figure 2 Kaplan-Meier estimates of polyp recurrence as indicated by surveillance 
polypectomy, stratified by cohort based on date of baseline colonoscopy with polypectomy.   
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Table 1 Characteristics of study population, N (%) 
Characteristics 1998-1999 
cohort 
N = 3,538 
2000-2001 
cohort 
N = 4,136 
2002-2003 
cohort 
N = 4,655 
Total 
 
N = 10,852 
Sex        
 Female 1,955 (55.3) 2,353 (56.9) 2,505 (53.8) 6,104 (56.3) 
 Male 1,583 (44.7) 1,783 (43.1) 2,150 (46.2) 4,748 (43.8) 
Age¥     
 66-69 639 (18.1) 426 (10.3) 297   (6.4) 1,068   (9.8) 
 70-74 1,106 (31.3) 1,498 (36.2) 1,617 (34.7) 3,661 (33.7) 
 75-79 978 (27.6) 1,231 (29.8) 1,558 (33.5) 3,348 (30.9) 
 80-84 529 (15.0) 645 (15.6) 815 (17.5) 1,830 (16.9) 
 85+ 286   (8.1) 336   (8.1) 368   (7.9) 945   (8.7) 
Race¥     
 White 3,003 (84.9) 3,443 (83.2) 3,830 (82.3) 9,022 (83.1) 
 Black 203   (5.7) 184   (4.5) 241   (5.2) 565   (5.2) 
 Other/Unknown* 332   (9.4) 509 (12.3) 584 (12.6) 1,265 (11.7) 
Urban/Rural     
 Urban 3,477 (98.3) 4,075 (98.5) 4,570 (98.2) 10,668 (98.3) 
 Rural/Missing* 61   (1.7) 61   (1.4) 85   (1.8) 184   (1.7) 
Charlson comorbidity score
†
     
 0 1,242 (35.1) 1,462 (35.4) 1,587 (34.1) 3,767 (34.7) 
 1 848 (24.0) 982 (23.7) 1,090 (23.4) 2,565 (23.6) 
 2 or more 1,448 (40.9) 1,692 (40.9) 1,978 (42.5) 4,520 (41.7) 
If surveillance event, type of 
event 
    
 Barium enema 37   (1.6) 27   (1.0) 29   (1.3) 84   (1.4) 
 Colonoscopy 2,269 (97.5) 2,385 (97.9) 2,167 (97.5) 5,862 (97.5) 
 Sigmoidoscopy 21   (0.9) 24   (1.0) 26   (1.2) 64   (1.1) 
¥ Statistically significant difference (p<0.01) between 98-99, 00-01 and 02-03 cohort 
* There were 31 beneficiaries with unknown race, and 32 with missing urban/rural status 
†
 Including comorbidities developed within 5 years after baseline colonoscopy (or until 
censoring or event) 
 
19 
 
Table 2 Odds ratio for failing to undergo a subsequent surveillance within 5 years after 
baseline colonoscopy among Medicare beneficiaries with a colonoscopy with polypectomy 
between 1998 and 2003 
Risk Factor Estimate (CI) 
Gender  
 Female 1           (referent) 
 Male 0.83 (0.77-0.90) ¥ 
Age group  
 66-69 years 1           (referent) 
 70-74 years 1.13   (0.99-1.29) 
 75-79 years 1.48 (1.29-1.69) ¥ 
 80-84 years 1.80 (1.55-2.09) ¥ 
 85 years and older 3.65 (3.01-4.43) ¥ 
Race   
 White 1           (referent) 
 Black 0.89   (0.75-1.06) 
 Other 0.99   (0.87-1.11) 
Charlson comorbidity  
 0 1           (referent) 
 1 1.37 (1.24-1.52) ¥ 
 2+ 2.16 (1.97-2.36) ¥ 
Cohort   
 1998-1999 1           (referent) 
 2000-2001 1.34 (1.22-1.47) ¥ 
 2002-2003 1.82 (1.66-1.99) ¥ 
Urban/rural status  
 Urban 1           (referent) 
 Rural 0.95   (0.83-1.08) 
 Missing 0.55   (0.28-1.08) 
¥ Statistically significant (p<0.01)  
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Table 3 Odds ratio for polyp recurrence as indicated by surveillance polypectomy among 
Medicare beneficiaries with a baseline colonoscopy with polypectomy between 1998 and 
2003 and a surveillance event within 5 years of that baseline colonoscopy 
Risk Factor Estimate (CI) 
Gender  
 Female 1           (referent) 
Male  1.38 (1.24-1.54) ¥ 
Age group  
 66-69 years 1           (referent) 
 70-74 years 0.97   (0.82-1.15) 
 75-79 years 0.99   (0.83-1.17) 
 80-84 years 0.85   (0.69-1.05) 
 85 years and older 0.89   (0.65-1.20) 
Race   
 White 1           (referent) 
 Black 0.77 (0.60-0.98) * 
 Other race 1.10   (0.93-1.31) 
Charlson comorbidity   
 0 1           (referent) 
 1 1.09   (0.95-1.25) 
 2+ 1.33 (1.17-1.51) ¥ 
Cohort   
 1998-1999 1           (referent) 
 2000-2001 0.92   (0.82-1.05) 
 2002-2003 0.88   (0.77-1.00) 
Urban/rural status  
 Urban 1           (referent) 
 Rural 1.07   (0.89-1.30) 
 Missing 1.56   (0.63-3.88) 
¥ Statistically significant (p<0.01)  
* Statistically significant (p<0.05)  
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Table 4 Probability of first surveillance event and first polypectomy event within 5 years 
after baseline colonoscopy with polypectomy among Medicare beneficiaries, stratified by 
cohort based on date of baseline colonoscopy with polypectomy – results of sensitivity 
analyses (estimated using the Kaplan-Meier method) 
Analysis* 1998-1999 
cohort 
2000-2001 
cohort 
2002-2003 
cohort 
Surveillance event      
 Base case1 58% 52% 45% 
 Include people with baseline sigmo2 60% 54% 46% 
 Single inclusion of individuals3 58% 49% 40% 
 Only colonoscopy surveillance4 57% 51% 44% 
 Include cancer cases5 64% 55% 45% 
Polyp recurrence    
 Base case1 36% 30% 26% 
 Include people with baseline sigmo2 36% 31% 26% 
 Single inclusion of individuals3 36% 28% 22% 
 Only colonoscopy surveillance4 36% 30% 26% 
 Include cancer cases5 42% 33% 26% 
*Results in the table refer to the following analyses: 1) original analysis; 2) Inclusion of 
patients with polyps detected and removed at (procto-) sigmoidoscopy; 3) Single inclusion 
of individuals in the cohort of their first colonoscopy with polypectomy between 1998 and 
2003; 4) Limiting the definition of a surveillance event to a colonoscopy; 5) Including 
people from the SEER-Medicare data with a cancer diagnosis 
  
